6th Edition of Global Conference on
Addiction Medicine, Behavioral Health and Psychiatry
October 20-22, 2025 | Orlando, Florida, USA
Neuropharmacology of Relapse in Substance Dependence
Relapse is a common and complex challenge in substance dependence, driven by alterations in the brain's reward and stress systems. Chronic substance use dysregulates neurotransmitters like dopamine, glutamate, and GABA, leading to cravings and reduced impulse control. Neuroplastic changes in the prefrontal cortex impair decision-making, while the amygdala's heightened sensitivity increases emotional triggers. Stress and environmental cues often act as catalysts for relapse. Pharmacological interventions such as naltrexone, buprenorphine, and anti-craving agents target these mechanisms to prevent relapse. Understanding the neurobiological underpinnings enables the development of personalized treatment plans, combining medication with behavioral therapies to address the root causes and promote long-term abstinence.
Nile Stanley
University of North Florida, United States
Ann Marie Leonard Zabel
Curry College, United States
Denis Larrivee
University of Navarra, Spain
Scharbach Hugues
Paris University, France
Alphonsus Obayuwana
Triple-H Project LLC, United States
Malasri Chaudhery Malgeri
Recovery com, United States
Jana Furstova
Palacký University Olomouc, Czech RepublicSubmit your abstract Today
Title : Tailoring biblio-poetry therapies using AI and biofeedback for addiction treatment
Nile Stanley, University of North Florida, United States
Title : The A-B-C of happiness coaching
Alphonsus Obayuwana, Triple-H Project LLC, United States
Title : Clinical pharmacology of marijuana: Update 2024
Frederick J Goldstein, Philadelphia College of Osteopathic Medicine, United States
Title : Trait-based recovery: Evidence-based trait activation to reduce depression, anxiety, and improve client engagement in addiction treatment
Jason Glenn Roop, The Center for Trait-Based Transformation, United States
Title : An investigation of the factors responsible for ubstance abuse from a cognitive perspective based on a mixed method approach
Adewole Olukorede, Literary Edifice, Italy
Title : A Long-Acting Naltrexone Implant (for Opioid Use Disorder: First-in-Human Phase I Trial)
Steven M Cohen, Akyso Therapeutics, United States